Literature DB >> 1155480

Lysinuric protein intolerance.

O Simell, J Perheentupa, J Rapola, J K Visakorpi, L E Eskelin.   

Abstract

Lysinuric protein intolerance (LPI), an autosomal recessive defect of diamino acid transport, is characterized chemically by renal hyperdiaminoaciduria, especially lysinuria, and by impaired formation of urea with hyperammonemia after protein ingestion. Our 20 patients thrived during breast-feeding, but ingestion of cow's milk caused diarrhea and vomiting. When able to select their diet, they rejected all protein-rich foods. They were short staturated and had weak atrophic muscles, osteoporosis, hepatomegaly and often splenomegaly. Four patients were mentally retarded. Fifteen patients had leukocyte counts below 4,000/mm3, and 17 patients had platelet counts below 150,000/mm3. Serum lactate dehydrogenase activity was constantly increased, and transaminase and aldolase activities were often increased. In the infants' livers, changes were only revealed by electron microscopy: increased and vesicular smooth endoplasmic reticulum, and abundance of glycogen particles in the hepatocytes. In the older patients, light microscopy demonstrated clearly limited areas where hepatocytes had large pale cytoplasm and small pyknotic nuclei. The diamino acids lysine, arginine and ornithine had plasma concentrations only one-third to one-half the normal mean; the renal clearances were clearly increased. Oral diamino acid loading tests suggested impaired intestinal absorption. Urea is built in the liver through transformation of ornithine to arginine, and cleavage of arginine to ornithine and urea. The addition of ornithine to an intravenous I-alanine loading prevented the hyperammonemia and normalized the urea production. Therefore, the diet has been supplemented with arginine, and more protein has been added. This therapy has lead to a remarkable catch-up growth in some patients. The pathophysiology of LPI is explained. Because of defective intestinal absorption and incrased renal loss, the diamino acids have a low plasma concentration. Their transport from plasma to hepatocytes is also impaired, and the liver becomes deficient in ornithine. This retards the urea cycle, and leads to postprandial hyperammonemia and protein aversion. The presence of the transport defect in the hepatocytes distinguishes LPI from other hyperdibasicaminoacidurias.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155480     DOI: 10.1016/0002-9343(75)90358-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Nutrient intake in lysinuric protein intolerance.

Authors:  L M Tanner; K Näntö-Salonen; J Venetoklis; S Kotilainen; H Niinikoski; K Huoponen; O Simell
Journal:  J Inherit Metab Dis       Date:  2007-06-21       Impact factor: 4.982

3.  Varicella and varicella immunity in patients with lysinuric protein intolerance.

Authors:  M Lukkarinen; K Näntö-Salonen; O Ruuskanen; T Lauteala; S Säkö; M Nuutinen; O Simell
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

4.  A difficult diagnosis of lysinuric protein intolerance: association with glucose-6-phosphate dehydrogenase deficiency.

Authors:  R Parini; M Vegni; M Pontiggia; D Melotti; C Corbetta; A Rossi; L Piceni Sereni
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

5.  Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Authors:  Harri Niinikoski; Risto Lapatto; Matti Nuutinen; Laura Tanner; Olli Simell; Kirsti Näntö-Salonen
Journal:  JIMD Rep       Date:  2011-06-22

6.  Familial lysinuric protein intolerance presenting as coma in two adult siblings.

Authors:  P J Shaw; G Dale; D Bates
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

7.  Lysinuric protein intolerance mutation is not expressed in the plasma membrane of erythrocytes.

Authors:  D W Smith; C R Scriver; O Simell
Journal:  Hum Genet       Date:  1988-12       Impact factor: 4.132

8.  A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance.

Authors:  Bridget M Stroup; Ronit Marom; Xiaohui Li; Chih-Wei Hsu; Cheng-Yen Chang; Luan D Truong; Brian Dawson; Ingo Grafe; Yuqing Chen; Ming-Ming Jiang; Denise Lanza; Jennie Rose Green; Qin Sun; J P Barrish; Safa Ani; Audrey E Christiansen; John R Seavitt; Mary E Dickinson; Farrah Kheradmand; Jason D Heaney; Brendan Lee; Lindsay C Burrage
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

9.  Growth hormone studies in lysinuric protein intolerance.

Authors:  I Goto; T Yoshimura; Y Kuroiwa
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

10.  Hyperexcretion of homocitrulline in a Malaysian patient with lysinuric protein intolerance.

Authors:  Anasufiza Habib; Zabedah Md Yunus; Nor Azimah Azize; Gaik-Siew Ch'ng; Winnie Peitee Ong; Bee-Chin Chen; Ho-Torng Hsu; Ke-Juin Wong; James Pitt; Lock-Hock Ngu
Journal:  Eur J Pediatr       Date:  2013-01-29       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.